Coya Therapeutics Overview
Valuation check: COYA's ROE is -4.93%, above the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-4.93%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Coya Therapeutics (COYA) currently reports a ROE of -4.93%. That is above the sector sector average of -5.68%. Use the charts on this page to explore Coya Therapeutics's ROE history and peer comparisons.
Coya Therapeutics's ROE of -4.93% is higher than the its sector sector average of -5.68%. That is roughly 13.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Coya Therapeutics's current -4.93% should be judged against industry norms (sector average: -5.68%) and against COYA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -4.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for Coya Therapeutics, and consider following COYA for alerts when major investors trade the stock.
